The general build-versus-buy answer is simple and almost always right: buy by default, build by exception. A product spreads its development cost across every customer; you cannot beat that economics on a process that is not genuinely yours.
Medical publishing flips that default more often than most industries. Two reasons, and only one of them is the obvious one.
Reason one — the content may not be able to leave
The obvious one. Wiley, Wolters Kluwer and Elsevier all explicitly warn against uploading unpublished manuscripts or patient data into general-purpose LLMs. If a tool processes your content on infrastructure you do not control and cannot describe, it is disqualified for unpublished work regardless of quality.
That does not rule out buying — plenty of vendors host inside your tenancy or offer deployment models that satisfy this. But it removes a large part of the market before you start, and it means "buy" often costs more here than the equivalent tool costs elsewhere.
Reason two — the validation cost, which appears in neither column
This is the one that decides real cases and is almost never in the comparison.
In regulated work, buying a tool does not end your obligation. You must still validate your use of it — that it does what you rely on it doing, in your configuration, with evidence you can show. Vendor validation is not your validation. And every vendor upgrade is a change that may require re-qualification.
Building carries a validation cost too, obviously. But it is a cost you control and can scope, rather than one that arrives on the vendor's release schedule.
So the honest comparison is not "licence fee versus development cost". It is:
- Buy: licence + integration + validating your use + re-qualifying on their upgrade cycle, indefinitely.
- Build: development + validating what you built + maintaining it on your own schedule.
For a low-risk workflow that never touches a dossier, validation is light and buying wins comfortably. For anything inside GxP, the second and fourth items of the buy column are frequently larger than the licence — and that reverses answers that looked obvious.
The third option everyone forgets
Most of the real work is neither. It is the seam between two tools you already own.
The tools in this industry are good at stages. DistillerSR handles regulated systematic review. Veeva PromoMats handles MLR. Established language tools handle manuscript polish. None of them handles what is where, with whom, since when, against which version — which is why that state still lives in a spreadsheet, and why roughly 88% of spreadsheets containing errors is a compliance fact rather than a productivity one.
Nobody sells the join because the join is specific to your combination of tools. That is the textbook definition of the build exception, and it is usually far smaller than a platform project.
A three-question test
Run in order. Stop at the first clear answer.
- Does a validated tool already cover this job? If DistillerSR covers your systematic reviews or a Veeva capability you already licence covers your MLR, buy it. Do not build what you can configure.
- Can the content leave your infrastructure? If not, the market narrows to vendors who can deploy inside it — and if none fit, that is a genuine build case rather than a preference.
- Is the problem a stage, or the seam between stages? Stages are bought. Seams are built, and are usually where the time is actually going.
What we would tell you against our own interest
We build custom systems, so we are on the "build" side of this and you should read the following with that in mind.
Most medical publishing organisations should buy more than they build. The stage tools are mature and validating a bought tool is usually cheaper than building and validating your own. If a product covers your job, buy the product.
The exception is narrow and real: the seam, and the case where content genuinely cannot leave. Start at the tracker, because it is the seam with the least regulatory weight — process metadata rather than science — and it is where the worked arithmetic usually puts the largest single saving anyway.
For the wider picture see AI for medical publishing; for what covers which job, see AI tools for medical publishing.